Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26581403 | 0.82 | NR4A2 (0.35) | NR4A2 | |
| SCHEMBL20604953 | 0.81 | HASPIN (0.42) | NR4A2 | |
| SCHEMBL23809246 | 0.81 | MEN1 (0.43) | NR4A2MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL23809227 | 0.79 | TP53 (0.49) | LMNAMAPTNPSR1TDP1 | |
| SCHEMBL23809165 | 0.78 | MTNR1A (0.43) | NR4A2MTNR1AMTNR1B | |
| SCHEMBL23809218 | 0.77 | DRD2 (0.42) | NR4A2MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL23809238 | 0.74 | HSD17B2 (0.34) | NR4A2MTNR1AMTNR1BKCNH2 | |
| SCHEMBL10308903 | 0.73 | KDM4E (0.35) | MEN1KMT2ALMNAHTTNPSR1 | |
| SCHEMBL10308908 | 0.73 | HDAC6 (0.38) | LMNAMAPTTDP1 | |
| SCHEMBL23809402 | 0.73 | L3MBTL1 (0.47) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | NR4A2 2684/4885MTNR1A 1577/4885MTNR1B 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.